Thank you.
On the one hand, the board was repeatedly reminded by the president that regulatory development was the purview of Health Canada. On the other hand, board members were told that they were in a unique position to have an impact on regulatory development because they had privileged access to information in the formative stages.
There was also confusion about the scope of the board’s work, owing to the fact that the agency undertook several initiatives clearly aimed at having an impact on policy, like the international forum on cross-border reproductive care, and the CFAS SOCG meeting on elective single embryo transfer.
Some board members repeatedly asked for clarification regarding the correct process by means of which the board could provide informed, timely, effective input into Health Canada on regulatory development, but no clear process was ever developed.